Field Safety Notices about HemosIL VWF Activity

According to ALIMS (Agencija za lekove i medicinska sredstva), this field safety notices involved a device in Serbia that was produced by Instrumentation Laboratory Co..

What is this?

Field safety notices are communications sent out by medical device manufacturers or their representatives in relation to actions that they may be taking in relation to their product that is on the market. These are mainly for health workers, but also for users. They can include recalls and alerts.

Learn more about the data here
  • Type of Event
    Field Safety Notice
  • Date
  • Event Date Posted
  • Event Country
  • Event Source
  • Event Source URL
  • Notes / Alerts
    Serbian data is current through February 2018. All of the data comes from ALIMS (Agencija za lekove i medicinska sredstva), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Serbia.
  • Extra notes in the data
  • Reason
    The presence of human anti-bovine antibodies (habia) in a patient sample has been shown to cause an over-estimation of results with the hemosil von willebrand factor activity reagent. since levels of habia vary in the patient population, small to large shifts in vwf activity results are possible. patient samples that contain large amounts of this habia interference can exhibit significant positive bias. the effects of this worst case situation can change a patient result from abnormal to normal, with potentially severe impact to patient treatment.